Mustard Compounds

Name
Mustard Compounds
Accession Number
DBCAT000681
Description

Strong alkylating and immunosuppressive agents whose biological activity is based on the presence of bis(2-chloroethyl)- groups. Although otherwise structurally diverse, the compounds have in common the capacity to contribute alkyl groups to DNA. They are generally highly toxic but include among their number many widely used and effective antineoplastic agents.

Drugs
DrugDrug Description
Uracil mustardUsed for its antineoplastic properties.
MelphalanAn alkylating agent used to treat multiple myeloma, ovarian carcinoma, uveal melanoma with unresectable hepatic metastases, and for high-dose conditioning before hematopoietic stem cell transplant in patients.
Melphalan flufenamideA melphalan prodrug used to treat relapsed or refractory multiple myeloma.
ChlorambucilA chemotherapy agent used in the management of chronic lymphocytic leukemia and malignant lymphomas.
CyclophosphamideA nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.
MechlorethamineAn antineoplastic agent used to treat Hodgkin's disease, lymphosarcoma, and chronic myelocytic or lymphocytic leukemia.
IfosfamideAn alkylating and immunosuppressive agent used in chemotherapy for the treatment of cancers, including testicular cancer, ovarian cancer, cervical cancer, osteocarcinoma, bladder cancer, small cell lung cancer, and non-Hodgkin's lymphoma.
EstramustineAn antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting.
Quinacrine mustardNot Available
PalifosfamideInvestigated for use/treatment in cancer/tumors (unspecified), lymphoma (unspecified), and sarcoma.
PR-104Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
EvofosfamideInvestigated for use/treatment in solid tumors.
GlufosfamideInvestigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.
BendamustineAn antineoplastic nitrogen mustard agent used in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy.
MafosfamideMafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.
PerfosfamidePerfosfamide has been used in trials studying the treatment of Lymphoma, Neuroblastoma, and Multiple Myeloma and Plasma Cell Neoplasm.
PrednimustinePrednimustine has been used in trials studying the treatment of Lymphoma.
TrofosfamideTrofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.
Estramustine phosphateA nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
TallimustineAn alkylating agent previously investigated for it's antitumor activity but was stopped due to severe myelotoxicity.
Drugs & Drug Targets
DrugTargetType
Uracil mustardDNAtarget
MelphalanDNAtarget
MelphalanSolute carrier family 22 member 3transporter
MelphalanLarge neutral amino acids transporter small subunit 1transporter
MelphalanAlbumincarrier
MelphalanAlpha-1-acid glycoprotein 1carrier
MelphalanAsc-type amino acid transporter 1transporter
Melphalan flufenamideAminopeptidase Nenzyme
Melphalan flufenamideDNAtarget
ChlorambucilDNAtarget
ChlorambucilGlutathione S-transferase Penzyme
ChlorambucilSolute carrier organic anion transporter family member 1A2transporter
ChlorambucilGlutathione S-transferases (Cytosolic)enzyme
CyclophosphamideDNAtarget
CyclophosphamideCytochrome P450 2B6enzyme
CyclophosphamideCytochrome P450 2C9enzyme
CyclophosphamideCytochrome P450 3A4enzyme
CyclophosphamideCytochrome P450 2C19enzyme
CyclophosphamideCytochrome P450 2A6enzyme
CyclophosphamideCytochrome P450 2C18enzyme
CyclophosphamideCytochrome P450 2C8enzyme
CyclophosphamideCytochrome P450 3A5enzyme
CyclophosphamideNuclear receptor subfamily 1 group I member 2target
MechlorethamineDNAtarget
MechlorethamineCholinesteraseenzyme
IfosfamideCytochrome P450 2B6enzyme
IfosfamideDNAtarget
IfosfamideCytochrome P450 3A4enzyme
IfosfamideCytochrome P450 3A5enzyme
IfosfamideCytochrome P450 2C9enzyme
IfosfamideCytochrome P450 2C8enzyme
IfosfamideCytochrome P450 2A6enzyme
IfosfamideCytochrome P450 2C19enzyme
IfosfamideCytochrome P450 2C18enzyme
IfosfamideProstaglandin G/H synthase 1enzyme
IfosfamideNuclear receptor subfamily 1 group I member 2target
EstramustineEstrogen receptor betatarget
EstramustineEstrogen receptortarget
EstramustineMicrotubule-associated protein 2target
EstramustineMicrotubule-associated protein 1Atarget
EstramustineATP-dependent translocase ABCB1transporter
EstramustineCytochrome P450 3A4enzyme
Quinacrine mustardTrypanothione reductasetarget
PalifosfamideDNA (cytosine-5)-methyltransferase 1target
PR-104Tumor necrosis factortarget
BendamustineCytochrome P450 1A2enzyme
TallimustineDNAtarget
TallimustineC-X-C chemokine receptor type 2target